Cleminorexton for Narcolepsy Type 1 and Type 2
This study is looking into how well a medication called cleminorexton works compared to a placebo (an inactive capsule that looks the same) for people with Narcolepsy Type 1 (NT1) or Narcolepsy Type 2 (NT2). These conditions cause extreme daytime sleepiness. The main goal is to see if cleminorexton helps you stay awake longer, measured by a test called the Maintenance of Wakefulness Test (MWT) over 12 weeks. You might be able to join if you are 18 to 70 years old, have been diagnosed with NT1 or NT2, and are able to stop other medications for your condition. The study plans to enroll 222 participants.
- Study design
- This is an interventional study comparing cleminorexton to a placebo. It plans to enroll 222 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 12 weeks, which suggests follow-up for at least that duration.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
At a glance
Conditions
Where it's being run
15 sites across 8 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change from baseline in mean sleep latency (average of the first 4 trials) on the Maintenance of Wakefulness Test (MWT)Baseline to week 12